VVOS

Vivos Therapeutics Inc

• PUBT·1d ago

  Vivos Therapeutics CEO to present at Small Cap Showcase & WTR Insights

• TipRanks·1d ago

  Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance

• Benzinga·4d ago

  12 Health Care Stocks Moving In Friday's Intraday Session

• Benzinga·4d ago

  Vivos Therapeutics Enters Senior Debt-to-Equity Exchange Agreement With Streeterville Capital For Up To $4.5M

• PUBT·4d ago

  Vivos Therapeutics agrees to exchange up to $4.5 million Streeterville debt into preferred, common stock

• Dow Jones·4d ago

  Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

• Benzinga·5d ago

  CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

• Dow Jones·5d ago

  Vivos Therapeutics Price Target Raised to $3.10/Share From $3.00 by Ascendiant Capital

• Dow Jones·5d ago

  Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

• Benzinga·5d ago

  Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

• TipRanks·05/23 00:13

  Vivos Therapeutics Balances Rapid Growth With Cash Strain

• TipRanks·05/22 00:30

  Vivos Therapeutics Earnings Call: Growth Meets Cash Strain

• Seeking Alpha·05/20 20:29

  Vivos Therapeutics GAAP EPS of -$0.52 misses by $0.07, revenue of $5.14M beats by $0.79M

• TipRanks·05/20 20:22

  Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

• Reuters·05/20 20:19

  Vivos Therapeutics Q1 revenue jumps, driven by SCN acquisition